FIELD: biotechnology.
SUBSTANCE: invention relates to recombinant fusion proteins based on IL-2 and CD80, and can be used in medicine to treat cancer. A fusion protein was constructed to include the following sequentially connected from the N- to the C-terminus: (1) an extracellular domain of the CD80 protein, (2) a linker of 5-80 consecutive amino acids, (3) an Fc domain, (4) a linker of 1-50 consecutive amino acids, and (5) a variant IL-2 protein with at least two substitutions selected from the 38th, 42nd, 45th, 61st and 72nd amino acids in the amino acid sequence SEQ ID NO: 10.
EFFECT: invention provides the production of a fusion protein capable of activating natural killer cells and controlling the activity of regulatory T-cells (Treg).
21 cl, 89 dwg, 4 tbl, 26 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW MODIFIED IMMUNOGLOBULIN Fc-FRAGMENT FUNCTION PROTEIN AND ITS USE | 2020 |
|
RU2800919C2 |
| NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 | 2019 |
|
RU2818349C2 |
| IL-12 HETERODIMERIC FC FUSION PROTEINS | 2019 |
|
RU2819097C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| FUSION PROTEIN OF DCTN1 PROTEIN WITH RET PROTEIN | 2018 |
|
RU2813996C2 |
| FUNCTION PROTEIN AND ITS USE | 2019 |
|
RU2800923C2 |
| FUSION PROTEIN AND ITS USE | 2020 |
|
RU2811120C2 |
| RSV F MUTANT PROTEIN AND ITS APPLICATION | 2020 |
|
RU2807742C1 |
| NOVEL FUSION PROTEINS SPECIFIC FOR CD137 AND GPC3 | 2020 |
|
RU2814653C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
